Anzahl der Publikationen: 5
2017
Pott, C.; Delfau, M.; Macintyre, E.; Ribrag, V.; Klapper, W.; Unterhalt, M.; Kneba, M.; Hiddemann, W.; Hermine, O.; Kluin-Nelemans, H.; Dreyling, M. und Hoster, E.
(2017):
Implications of deep molecular response after induction and in maintenance treatment in elderly patients with mantle cell lymphoma: updated results of the randomized EU-MCL elderly trial.
In: Oncology Research and Treatment, Bd. 40: S. 13
2016
Hermine, Olivier; Hoster, Eva; Walewski, J.; Bosly, A.; Stilgenbauer, S.; Thieblemont, C.; Szymczyk, Michal; Bouabdallah, R.; Kneba, M.; Hallek, M.; Salles, G.; Feugier, P.; Ribrag, Vincent; Birkmann, J.; Forstpointner, R.; Haioun, C.; Hänel, M.; Casasnovas, R. O.; Finke, J.; Peter, N.; Bouabdallah, K.; Sebban, C.; Fischer, T.; Dührsen, U.; Metzner, B.; Maschmeyer, G.; Kanz, L.; Schmidt, C.; Delarue, R.; Brousse, N.; Klapper, Wolfram; Macintyre, E.; Delfau-Larue, M. H.; Pott, Christiane; Hiddemann, Wolfgang; Unterhalt, Michael und Dreyling, Martin
(2016):
Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network.
In: Lancet, Bd. 388, Nr. 10044: S. 565-575
2015
Delfau-Larue, M. H.; Klapper, Wolfram; Berger, F.; Jardin, F.; Briere, J.; Salles, G.; Casasnovas, O.; Feugier, P.; Haioun, C.; Ribrag, Vincent; Thieblemont, C.; Unterhalt, Michael; Dreyling, Martin; Macintyre, E.; Pott, Christiane; Hermine, Olivier und Hoster, Eva
(2015):
High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma.
In: Blood, Bd. 126, Nr. 5: S. 604-611
Cheminant, M.; Derrieux, C.; Touzart, A.; Schmit, S.; Grenier, A.; Trinquand, A.; Delfau-Larue, M. H.; Lhermitte, L.; Thieblemont, C.; Ribrag, Vincent; Cheze, S.; Sanhes, L.; Jardin, F.; Lefrere, F.; Delarue, R.; Hoster, Eva; Dreyling, Martin; Asnafi, V.; Hermine, Olivier und Macintyre, E.
(2015):
Minimal Residual Disease monitoring by 8-color flow cytometry in Mantle Cell Lymphoma: an EU-MCL and LYSA study.
In: Haematologica, Bd. 101, Nr. 3: S. 336-345
2010
Pott, Christiane; Hoster, Eva; Delfau-Larue, M. H.; Beldjord, K.; Böttcher, S.; Asnafi, V.; Plonquet, A.; Siebert, R.; Callet-Bauchu, E.; Andersen, N.; van Dongen, J. J.; Klapper, Wolfram; Berger, F.; Ribrag, Vincent; van Hoof, A. L.; Trneny, Marek; Walewski, J.; Dreger, P.; Unterhalt, Michael; Hiddemann, Wolfgang; Kneba, M.; Kluin-Nelemans, H. C.; Hermine, Olivier; Macintyre, E. und Dreyling, Martin
(2010):
Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study.
In: Blood, Bd. 115, Nr. 16: S. 3215-3223
Diese Liste wurde am
Sat Dec 21 19:41:36 2024 CET
erstellt.